B-cell Non Hodgkin Lymphoma
Showing 1 - 25 of >10,000
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023
Non-hodgkin Lymphoma Trial (HY004)
Not yet recruiting
- Non-hodgkin Lymphoma
- HY004
- (no location specified)
Aug 21, 2023
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- SHR-A1912; R-Chemo
- (no location specified)
Oct 23, 2023
B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- IMM0306
- Lenalidomide capsule
- (no location specified)
Mar 6, 2023
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)
Not yet recruiting
- Lymphoma, Non-Hodgkin
-
Perth, Western Australia, AustraliaLinear Clinical Research Ltd
Apr 20, 2023
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- CB dualCAR-NK19/70
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022
B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)
Recruiting
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- UCART20x22
- CLLS52
-
Austin, TexasSarah Cannon - St. David South Austin Medical Center
Dec 8, 2022
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma Trial in Duarte (Best Practice, Cognitive Intervention, Comprehensive Geriatric
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma
- Best Practice
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 19, 2023
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)
Completed
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
-
Isehara, Kanagawa, Japan
- +1 more
Apr 6, 2022
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)
Not yet recruiting
- Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- JS203 for Injection
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 11, 2022
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)
Not yet recruiting
- Mature B-Cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
- (no location specified)
Sep 6, 2022
SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- +2 more
- (no location specified)
Jun 22, 2023
Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive
Active, not recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- fractionated first dose rituximab
-
Geneva, SwitzerlandUniversity Hospital Geneva
Apr 21, 2023
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
-
Scottsdale, Arizona
- +7 more
Aug 19, 2022
Non-hodgkin Lymphoma, B Cell Trial in Switzerland (ctDNA detection)
Not yet recruiting
- Non-hodgkin Lymphoma, B Cell
- ctDNA detection
-
Aarau, Switzerland
- +12 more
Oct 18, 2023